NCT06224387View on ClinicalTrials.gov

CTS2190 Phase I /II Clinical Study in Patients

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

224

Participants

Timeline

Start Date

June 26, 2023

Primary Completion Date

July 31, 2025

Study Completion Date

October 31, 2025

Conditions
Solid TumorsPancreatic CancerNon-small Cell Lung CancerTriple-negative Breast Cancer
Interventions
DRUG

CTS2190 capsules

4-6 dose groups are pre-specified in Dose Escalation,and 4 arms in Dose Expansion.

Trial Locations (2)

310022

RECRUITING

Zhejiang Cancer Hospital, Hangzhou

471000

RECRUITING

The First Affiliated Hospital of Henan University of Science and Technology, Luoyang

Sponsors
All Listed Sponsors
lead

CytosinLab Therapeutics Co., Ltd.

INDUSTRY

NCT06224387 - CTS2190 Phase I /II Clinical Study in Patients | Biotech Hunter | Biotech Hunter